Bone‐ and Cartilage‐Protective Effects of a Monoclonal Antibody Against Colony‐Stimulating Factor 1 Receptor in Experimental Arthritis
Open Access
- 12 March 2014
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (11) , 2989-3000
Abstract
Objective: Colony‐stimulating factor 1 receptor (CSF‐1R) essentially modulates monocyte proliferation, migration, and activation, which are considered important for the pathogenesis of rheumatoid arthritis (RA). We undertook this study to determine CSF‐1R expression in human RA as well as the efficacy of a specific anti–CSF‐1R monoclonal antibody (AFS98) in 2 different animal models of RA.Methods: CSF‐1R expression was examined in blood, synovium, and bone samples from RA patients, osteoarthritis (OA) patients, and healthy subjects. The efficacy of AFS98 was examined by clinical assessment, histology, and bone histomorphometry in collagen‐induced arthritis (CIA) and serum‐transfer arthritis.Results: CSF‐1R expression was increased in the synovium of RA patients compared to OA patients and healthy controls in fibroblast‐like synoviocytes, follicular dendritic cells, macrophages, and osteoclasts. Circulating RA monocytes and neutrophils but not lymphocytes were CSF‐1R+. In mice, blockade of CSF‐1R abrogated cartilage damage, bone erosion, and systemic bone loss, and this was associated with the depletion of osteoclasts in both models. While blockade of CSF‐1R did not affect inflammation in passive serum‐transfer arthritis, it significantly reduced inflammation in CIA, and this was associated with the absence of synovial macrophages and reduced splenic CD11b+Gr‐1− monocytes.Conclusion: CSF‐1R was broadly expressed in human RA. Blockade of CSF‐1R protected against bone and cartilage destruction in both mouse models and also showed significant antiinflammatory effects in the CIA model. These data provide evidence for CSF‐1R as a therapeutic target in RA.Keywords
Funding Information
- Transgene SA
This publication has 49 references indexed in Scilit:
- Therapeutic Effects of Anti-CD115 Monoclonal Antibody in Mouse Cancer Models through Dual Inhibition of Tumor-Associated Macrophages and OsteoclastsPLOS ONE, 2013
- Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesisArthritis Research & Therapy, 2012
- Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patientsAnnals of the Rheumatic Diseases, 2012
- M-CSF Potently Augments RANKL-Induced Resorption Activation in Mature Human OsteoclastsPLOS ONE, 2011
- An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammationBlood, 2010
- Association between colony-stimulating factor 1 receptor gene polymorphisms and asthma riskHuman Genetics, 2010
- c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritisArthritis Research & Therapy, 2010
- Incomplete restoration of colony-stimulating factor 1 (CSF-1) function in CSF-1–deficient Csf1op/Csf1op mice by transgenic expression of cell surface CSF-1Blood, 2004
- M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone lossJournal of Clinical Investigation, 2000
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995